Shots:
- TriLink & Aldevron have entered into a non-exclusive license & supply agreement for TriLink’s patented CleanCap mRNA capping tech, allowing Aldevron’s clients to use it for developing mRNA-based therapeutics & vaccines
- As per the agreement, TriLink will provide CleanCap M6, CleanCap AG 3’OMe, CleanCap AG, & CleanCap AU cap analogs to Aldevron for mRNA development & manufacturing from pre-clinical to P-III programs
- CleanCap tech generates optimal 5’Cap structures with ~95% efficiency, improving mRNA yield & process time over traditional methods, with studies showing that CleanCap M6 boosts mRNA expression by >30% vs enzymatic capping
Ref: BusinessWire | Image: TriLink & Aldevron
Related News:- Vanda Pharmaceuticals Enters into an Exclusive Global License Agreement with AnaptysBio to Develop and Commercialize Imsidolimab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
